| Name | Title | Contact Details |
|---|
We love the challenge of bringing order to the chaos. Based in Rockford, IL, we’re proud of our Midwestern work ethic and the fact that we are independent “doers,” not just consultants or software specialists. We believe in getting our hands dirty by digging into the data and being your only business process resource during the entire implementation process.
PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs; and FTE services. The company was listed on Shenzhen Exchange Stock in China on November 10, 2017. PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Building on that success, the company acquired Shandong Diai Biotechnology Co., Ltd. as its pilot plant and manufacturing site in 2016, and is providing scale-up synthesis and manufacturing of key intermediates/RSMs. PharmaBlock is now committed to a more comprehensive and long-term service to valued customers.
Shelby Residental and Vocational Services is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vigil Health Solutions Inc. is a Victoria, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.